Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17264
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerucca, Piero-
dc.contributor.authorScheffer, Ingrid E-
dc.contributor.authorKiley, Michelle-
dc.date.accessioned2018-03-21T05:17:25Z-
dc.date.available2018-03-21T05:17:25Z-
dc.date.issued2018-03-19-
dc.identifier.citationMedical Journal of Australia 2018; 208(5): 226-233en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17264-
dc.description.abstractThe International League Against Epilepsy has recently published a new classification of epileptic seizures and epilepsies to reflect the major scientific advances in our understanding of the epilepsies since the last formal classification 28 years ago. The classification emphasises the importance of aetiology, which allows the optimisation of management. Antiepileptic drugs (AEDs) are the main approach to epilepsy treatment and achieve seizure freedom in about two-thirds of patients. More than 15 second generation AEDs have been introduced since the 1990s, expanding opportunities to tailor treatment for each patient. However, they have not substantially altered the overall seizure-free outcomes. Epilepsy surgery is the most effective treatment for drug-resistant focal epilepsy and should be considered as soon as appropriate trials of two AEDs have failed. The success of epilepsy surgery is influenced by different factors, including epilepsy syndrome, presence and type of epileptogenic lesion, and duration of post-operative follow-up. For patients who are not eligible for epilepsy surgery or for whom surgery has failed, trials of alternative AEDs or other non-pharmacological therapies, such as the ketogenic diet and neurostimulation, may improve seizure control. Ongoing research into novel antiepileptic agents, improved techniques to optimise epilepsy surgery, and other non-pharmacological therapies fuel hope to reduce the proportion of individuals with uncontrolled seizures. With the plethora of gene discoveries in the epilepsies, "precision therapies" specifically targeting the molecular underpinnings are beginning to emerge and hold great promise for future therapeutic approaches.en
dc.language.isoeng-
dc.subjectAnticonvulsantsen
dc.subjectEpilepsyen
dc.subjectNeuropharmacologyen
dc.subjectPharmacogenomicsen
dc.titleThe management of epilepsy in children and adults.en
dc.typeJournal Articleen
dc.identifier.journaltitleMedical Journal of Australiaen
dc.identifier.affiliationRoyal Melbourne Hospital, Melbourne, VICen
dc.identifier.affiliationEpilepsy Research Centre, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationRoyal Adelaide Hospital, Adelaide, SAen
dc.type.contentTexten
dc.identifier.orcid0000-0002-2311-2174en
dc.identifier.pubmedid29540143-
dc.type.austinJournal Article-
local.name.researcherPerucca, Piero
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptNeurology-
crisitem.author.deptComprehensive Epilepsy Program-
crisitem.author.deptEpilepsy Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.